Related references
Note: Only part of the references are listed.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Prevention and treatment of bone metastases
Robert E. Coleman
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
G. Viale et al.
ANNALS OF ONCOLOGY (2011)
Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer
Eun-Kyu Kim et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
PKA-induced phosphorylation of ER alpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer
Marleen Kok et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole - of clinical importance?
J. Geisler
BRITISH JOURNAL OF CANCER (2011)
Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
Zsuzsanna Bago-Horvath et al.
CLINICAL CANCER RESEARCH (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer
Chungyeul Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Predictive algorithms for adjuvant therapy: TransATAC
Mitch Dowsett et al.
STEROIDS (2011)
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes
Yinghui Zhang et al.
BREAST CANCER RESEARCH (2011)
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
Xianglin Wu et al.
BREAST CANCER RESEARCH (2011)
AIB1 is a predictive factor for tamoxifen response in premenopausal women
S. Alkner et al.
ANNALS OF ONCOLOGY (2010)
A polymorphism at the 3′-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
Zaida Garcia-Casado et al.
BMC CANCER (2010)
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
Bostjan Seruga et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Liewei Wang et al.
CANCER RESEARCH (2010)
Naked CanScript, an 18-base pair sequence, has tumor cell-specific promoter activity in vivo: Implications for targeted gene therapy
Janet A. Sawicki et al.
CANCER RESEARCH (2010)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?
Amna Sheri et al.
CLINICAL BREAST CANCER (2010)
Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Josefine Bostner et al.
CLINICAL CANCER RESEARCH (2010)
New Strategies in Estrogen Receptor-Positive Breast Cancer
Stephen R. D. Johnston
CLINICAL CANCER RESEARCH (2010)
Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
Said Akli et al.
CLINICAL CANCER RESEARCH (2010)
17β-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
Ann-Christine Kallstrom et al.
EUROPEAN JOURNAL OF CANCER (2010)
p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients
Maria Stendahl et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Differential Requirements of Hsp90 and DNA for the Formation of Estrogen Receptor Homodimers and Heterodimers
Emily Powell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Management of breast cancer with targeted agents: importance of heterogenicity
Serena Di Cosimo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Biomarkers and surrogate end points-the challenge of statistical validation
Marc Buyse et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors
Kazuyoshi Motomura et al.
ONCOLOGY (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
Piiha-Lotta Jerevall et al.
BREAST CANCER RESEARCH (2010)
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer
Katrine L. Henriksen et al.
ACTA ONCOLOGICA (2009)
The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells
Xianglin Wu et al.
CANCER RESEARCH (2009)
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer
Hiroko Yamashita et al.
CANCER SCIENCE (2009)
Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
Vincent O. Dezentje et al.
CLINICAL CANCER RESEARCH (2009)
Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients
Agneta Jansson et al.
CLINICAL CANCER RESEARCH (2009)
Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence
Aisling M. Redmond et al.
CLINICAL CANCER RESEARCH (2009)
Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
Liane M. McGlynn et al.
CLINICAL CANCER RESEARCH (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer
C. Holm et al.
JOURNAL OF PATHOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
Marleen Kok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Estrogen receptor beta in breast cancer-Diagnostic and therapeutic implications
Johan Hartman et al.
STEROIDS (2009)
Plasma membrane estrogen receptors
Ellis R. Levin
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
Jennifer H. Law et al.
CANCER RESEARCH (2008)
Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer
Daniele Generali et al.
CLINICAL CANCER RESEARCH (2008)
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
Ramon Colomer et al.
CLINICAL CANCER RESEARCH (2008)
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
Margaretha Rudas et al.
CLINICAL CANCER RESEARCH (2008)
Low phosphorylation of estrogen receptor a (ER alpha) serine 118 and high phosphorylation of ER alpha serine 167 improve survival in ER-positive breast cancer
Hiroko Yamashita et al.
ENDOCRINE-RELATED CANCER (2008)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer
Dedra H. Fagan et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways
Stephen Safe et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Letting the genome out of the bottle - Will we get our wish?
David J. Hunter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas (Publication with Expression of Concern. See vol. 17, 2022)
Valentina Folgiero et al.
PLOS ONE (2008)
Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer
D. Al-Azawi et al.
ONCOGENE (2008)
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
Lisa Ryden et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer
Ander Urruticoechea et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
Katja Lundgren et al.
BREAST CANCER RESEARCH (2008)
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
Mattia Barbareschi et al.
CLINICAL CANCER RESEARCH (2007)
Phosphorylation of estrogen receptor-α at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients
Jie Jiang et al.
CLINICAL CANCER RESEARCH (2007)
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer
J. Bostner et al.
ONCOGENE (2007)
PKA-induced resistance to tamoxifen is associated with an altered orientation of ERα towards co-activator SRC-1
Wilbert Zwart et al.
EMBO JOURNAL (2007)
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor -: Positive premenopausal breast cancer
Jennifer M. Giltnane et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Gizeh Perez-Tenorio et al.
CLINICAL CANCER RESEARCH (2007)
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Frederik Holst et al.
NATURE GENETICS (2007)
Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients
Tove Kirkegaard et al.
CLINICAL CANCER RESEARCH (2007)
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
Naomi Maruyama et al.
CLINICAL CANCER RESEARCH (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity
Varsha S. Likhite et al.
MOLECULAR ENDOCRINOLOGY (2006)
Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
N. Sarwar et al.
ENDOCRINE-RELATED CANCER (2006)
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
Maria Stendahl et al.
CLINICAL CANCER RESEARCH (2006)
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
Caroline Holm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen
Jenny Bergqvist et al.
EUROPEAN JOURNAL OF CANCER (2006)
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
M Dowsett et al.
ANNALS OF ONCOLOGY (2006)
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer
E Tokunaga et al.
EUROPEAN JOURNAL OF CANCER (2006)
PIK3CA mutations in breast cancer are associated with poor outcome
SY Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy
CK Osborne et al.
BREAST (2005)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
K Jirström et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Stability of phosphoprotein as a biological marker of tumor signaling
AF Baker et al.
CLINICAL CANCER RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer
H Yamashita et al.
BREAST CANCER RESEARCH (2005)
Phospho-serine-118 estrogen receptor-α detection in human breast tumors in vivo
L Murphy et al.
CLINICAL CANCER RESEARCH (2004)
Coregulator function: A key to understanding tissue specificity of selective receptor modulators
CL Smith et al.
ENDOCRINE REVIEWS (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer
R Michalides et al.
CANCER CELL (2004)
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
XJ Ma et al.
CANCER CELL (2004)
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype
J Frasor et al.
ENDOCRINOLOGY (2003)
Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression
SF Doisneau-Sixou et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Review of the in vivo functions of the p160 steroid receptor coactivator family
JM Xu et al.
MOLECULAR ENDOCRINOLOGY (2003)
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer
PN Span et al.
ONCOGENE (2003)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
JM Knowlden et al.
ENDOCRINOLOGY (2003)
Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors
K Christov et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer
RR Love et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
DS Chen et al.
ONCOGENE (2002)
The role of mitogen-activated protein (MAP) kinase in breast cancer
RJ Santen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2002)
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
R Michalides et al.
BRITISH JOURNAL OF CANCER (2002)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance
RA Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma:: comparison with biochemical determination in a prospective study of 793 cases
B Zafrani et al.
HISTOPATHOLOGY (2000)
Share Paper
